ArticleFrontiers in oncology2026
Evolving patterns of bladder cancer mortality in US adults: a two-decade analysis reveals persistent disparities despite overall progress (1999-2020).
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mortality trends in the co-occurrence of urinary tract cancer and diabetes mellitus.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Bladder cancer represents one of the most common malignancies in the United States, with mortality trends reflecting disease burden and clinical management effectiveness. This study aimed to comprehensively analyze long-term trends and demographic disparities in bladder cancer mortality among US adults from 1999 to 2020 using national data. Methods: Mortality data with bladder cancer (ICD-10 code: C67) as the underlying cause of death were extracted from the CDC WONDER database for 1999-2020.AAMR was calculated. Joinpoint regression models were employed to calculate APC and AAPC to identify temporal trends and inflection points in mortality rates. Stratified analyses were conducted by sex, age group, race/ethnicity, urbanization level, and geographic region. Results: From 1999 to 2020, a total of 319,229 adult deaths in the United States had bladder cancer as the underlying cause of death. Overall age-adjusted mortality rates declined from 6.737 per 100,000 in 1999 to 6.159 per 100,000 in 2020 (AAPC: -0.410, 95% CI: -0.495 to -0.310, P < 0.001). Joinpoint regression analysis revealed a significant decline trend after 2016 (APC changed from -0.347 to -2.118). Stratified analysis showed that male mortality rates were significantly higher than female rates. White populations had the highest recorded mortality rate (7.003 per 100,000), though this likely reflects diagnostic coding biases rather than true biological differences. Regional disparities existed, with the Northeast showing the highest mortality rates. Non-metropolitan residents had higher mortality rates (6.887 per 100,000) compared to metropolitan residents (6.64 per 100,000). Conclusion: Over the past two decades, bladder cancer mortality among US adults has demonstrated an overall declining trend, reflecting advances in diagnostic and therapeutic technologies. However, significant disparities by sex, race, and geographic region persist, indicating prominent health inequality issues. Future efforts should focus on strengthening early screening, smoking cessation interventions, and standardized treatment for high-risk populations to further reduce disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.